World's Best Scientists 2026 revealed!
Award Badge
Medicine
UK
2023

D-Index & Metrics

Immunology

D-Index
148
Citations
91983
World Ranking
127
National Ranking
13

Medicine

D-Index
149
Citations
92237
World Ranking
1193
National Ranking
126

Paul P. Tak publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Paul P. Tak sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 771 publications — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Paul P. Tak D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Paul P. Tak sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 148 D-Index — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in United Kingdom Leader Award

Overview

Paul P. Tak is affiliated with GlaxoSmithKline in the United Kingdom. Their research spans multiple fields within medicine and molecular biology, with a significant focus on clinical and translational studies.

Their main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these fields, their subfields of study are:

  • Oncology
  • Genetics
  • Rheumatology
  • Immunology
  • Pathology and Forensic Medicine

The topics most frequently addressed in their work are:

  • Rheumatoid Arthritis Research and Therapies
  • Virus-based gene therapy research
  • CAR-T cell therapy research
  • Cancer Research and Treatments
  • Cancer Immunotherapy and Biomarkers
  • Lymphoma Diagnosis and Treatment
  • Systemic Lupus Erythematosus Research

Paul P. Tak has contributed publications to several journals and conference programs, with frequent publications in the following venues:

  • Regular and Young Investigator Award Abstracts
  • The Lancet Rheumatology
  • Journal of Clinical Oncology
  • Neuro-Oncology
  • Arthritis Research & Therapy

Recent publications include:

  • "Clinical trial links oncolytic immunoactivation to survival in glioblastoma" (2023, Nature)
  • "A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome" (2022, JCI Insight)
  • "A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis" (2021, BMJ Open Gastroenterology)
  • "A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis" (2021, Arthritis Research & Therapy)
  • "Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled Study" (2020, Clinical Pharmacology & Therapeutics)

The scientist collaborates frequently with several colleagues, including:

  • Francesca Barone
  • Laura K. Aguilar
  • Andrea G. Manzanera
  • Estuardo Aguilar-Córdova
  • David Krisky

Best Publications

  • 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

    Daniel Aletaha;Tuhina Neogi;Alan J. Silman;Julia Funovits

  • NF-κB: a key role in inflammatory diseases

    Paul P. Tak;Gary S. Firestein

  • Genetics of rheumatoid arthritis contributes to biology and drug discovery

    Yukinori Okada;Yukinori Okada;Di Wu;Di Wu;Di Wu;Gosia Trynka;Gosia Trynka;Towfique Raj;Towfique Raj

  • Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

    Daniel Tracey;Lars Klareskog;Eric H. Sasso;Jochen G. Salfeld

  • Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci

    Eli A Stahl;Soumya Raychaudhuri;Soumya Raychaudhuri;Elaine F Remmers;Gang Xie

  • Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

    Wolfgang Hueber;Dhavalkumar D. Patel;Thaddeus Dryja;Andrew M. Wright

  • Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis

    Frieda A. Koopman;Sangeeta S. Chavan;Sanda Miljko;Simeon Grazio

  • MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins.

    Yuanjia Tang;Xiaobing Luo;Huijuan Cui;Xuming Ni

  • Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

    Geertje M Bartelds;Carla A Wijbrandts;Michael T Nurmohamed;Steven Stapel

  • Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity

    P. P. Tak;T. J. M. Smeets;M. R. Daha;P. M. Kluin

  • Common variants at CD40 and other loci confer risk of rheumatoid arthritis

    Soumya Raychaudhuri;Soumya Raychaudhuri;Soumya Raychaudhuri;Elaine F Remmers;Annette T Lee;Rachel Hackett

  • Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

    Gerrit Jan Wolbink;Marijn Vis;Willem Lems;Alexandre E. Voskuyl

  • European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

    L Gossec;J S Smolen;C Gaujoux-Viala;Z Ash

  • Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis

    Jasper J. Haringman;Danielle M. Gerlag;Aeilko H. Zwinderman;Tom J.M. Smeets

  • The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis.

    Paul Peter Tak;Barry Bresnihan

  • EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis

    Danielle M. Gerlag;Karim Raza;Lisa G M van Baarsen;Elisabeth Brouwer

  • The resolution of inflammation.

    Christopher D. Buckley;Derek W. Gilroy;Charles N. Serhan;Brigitta Stockinger

  • Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis.

    P P Tak;P C Taylor;F C Breedveld;T J Smeets

  • Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

    Iain B. McInnes;Joachim Sieper;Juergen Braun;Paul Emery

  • Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides.

    I M van der Heijden;B Wilbrink;I Tchetverikov;I A Schrijver

Frequent Co-Authors

Danielle M. Gerlag
Danielle M. Gerlag UCB Pharma (United Kingdom)
Dominique Baeten
Dominique Baeten University of Amsterdam
Ferdinand C. Breedveld
Ferdinand C. Breedveld Leiden University Medical Center
Paul Emery
Paul Emery University of Leeds
Tom W. J. Huizinga
Tom W. J. Huizinga Leiden University Medical Center
Robert M. Plenge
Robert M. Plenge Bristol Myers Squibb
Lars Klareskog
Lars Klareskog Karolinska Institute
Gary S. Firestein
Gary S. Firestein University of California, San Diego
Soumya Raychaudhuri
Soumya Raychaudhuri Brigham and Women's Hospital
Frank Baas
Frank Baas Leiden University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, related healthcare fields like nursing offer dynamic career paths. Many students are attracted to accelerated formats such as the 12-month accelerated nursing programs, which allow for quicker entry into the workforce without sacrificing education quality.

For beginners or those seeking a more accessible nursing route, there are lpn programs easy to get into that provide foundational knowledge and hands-on experience. These programs can serve as stepping stones toward advanced practice.

If advancing further is the goal, exploring which nurse practitioner program is easiest can help balance workload and learning speed. Such programs cater to professionals aiming for specialized roles in healthcare.

For those drawn to mental health aspects of immunology and healthcare, the top pmhnp programs offer excellent clinical placements and prepare students for impactful psychiatric-mental health nursing careers.

Best Scientists Citing Paul P. Tak

Trending Scientists